These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 14561942)

  • 21. Effects of endothelin antagonist tezosentan on orthodontic tooth movement in rats.
    Drevensek M; Sprogar S; Boras I; Drevensek G
    Am J Orthod Dentofacial Orthop; 2006 Apr; 129(4):555-8. PubMed ID: 16627184
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical Trials Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001.
    Louis A; Cleland JG; Crabbe S; Ford S; Thackray S; Houghton T; Clark A
    Eur J Heart Fail; 2001 Jun; 3(3):381-7. PubMed ID: 11378012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Shah MR; Kobrin I; Frey A; Gheorghiade M
    Am Heart J; 2002 Oct; 144(4):583-8. PubMed ID: 12360152
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel endothelin receptor antagonist attenuates endotoxin-induced lung injury in sheep.
    Kuklin VN; Kirov MY; Evgenov OV; Sovershaev MA; Sjöberg J; Kirova SS; Bjertnaes LJ
    Crit Care Med; 2004 Mar; 32(3):766-73. PubMed ID: 15090960
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of neurohormonal activation in the pathophysiology and prognosis of patients with congestive heart failure.
    Kubo SH
    Coron Artery Dis; 1993 Jan; 4(1):4-15. PubMed ID: 7903590
    [No Abstract]   [Full Text] [Related]  

  • 26. Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4).
    O'Connor CM; Gattis WA; Adams KF; Shah MR; Frey A; Gheorghiade M;
    Am Heart J; 2003 Feb; 145(2 Suppl):S58-9. PubMed ID: 12594454
    [No Abstract]   [Full Text] [Related]  

  • 27. Tezosentan. Actelion/Genentech.
    Rossetti E; De Servi S
    Curr Opin Investig Drugs; 2003 Mar; 4(3):323-8. PubMed ID: 12735233
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Endothelin antagonists: new bullets against lung injury?
    Leeman M
    Crit Care; 2005 Jun; 9(3):245-6. PubMed ID: 15987411
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Endothelin and the vascular choir in heart failure.
    Stevenson LW; Fonarow GC
    J Am Coll Cardiol; 1992 Oct; 20(4):854-7. PubMed ID: 1326570
    [No Abstract]   [Full Text] [Related]  

  • 30. Effects of tezosentan, a dual endothelin receptor antagonist, on the cardiovascular and renal systems of neonatal piglets during endotoxic shock.
    Chin A; Radhakrishnan J; Fornell L; John E
    J Pediatr Surg; 2002 Mar; 37(3):482-7. PubMed ID: 11877672
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neurohumoral aspects of heart failure.
    Benedict CR
    Cardiol Clin; 1994 Feb; 12(1):9-23. PubMed ID: 7910114
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endothelin receptor blockade and exacerbation of heart failure.
    Szokodi I; Piuhola J; Ruskoaho H
    Circulation; 2003 Jun; 107(22):e211. PubMed ID: 12796421
    [No Abstract]   [Full Text] [Related]  

  • 33. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Endothelin antagonism in heart failure.
    Webb DJ
    Circulation; 1995 Dec; 92(12):3372. PubMed ID: 8521551
    [No Abstract]   [Full Text] [Related]  

  • 34. 1,3-Diarylindan-2-carboxylic acids, potent and selective non-peptide endothelin receptor antagonists.
    Elliott JD; Lago MA; Cousins RD; Gao A; Leber JD; Erhard KF; Nambi P; Elshourbagy NA; Kumar C; Lee JA
    J Med Chem; 1994 May; 37(11):1553-7. PubMed ID: 8201588
    [No Abstract]   [Full Text] [Related]  

  • 35. Tezosentan, a combined parenteral endothelin receptor antagonist, produces pulmonary vasodilation in lambs with acute and chronic pulmonary hypertension.
    Fitzgerald RK; Oishi P; Ovadia B; Ross GA; Reinhartz O; Johengen MJ; Fineman JR
    Pediatr Crit Care Med; 2004 Nov; 5(6):571-7. PubMed ID: 15530195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Neurohormonal activation in congestive heart failure: does it normalize after heart transplantation?].
    Pérez-Villa F; Roig E; Ferrer E; Cuppoletti A; Llancaqueo M; Jiménez W; Sanz G
    Rev Esp Cardiol; 2004 Aug; 57(8):725-31. PubMed ID: 15282060
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanisms of neurohormonal activation in chronic congestive heart failure: pathophysiology and therapeutic implications.
    Dávila DF; Núñez TJ; Odreman R; de Dávila CA
    Int J Cardiol; 2005 Jun; 101(3):343-6. PubMed ID: 15907399
    [TBL] [Abstract][Full Text] [Related]  

  • 38. sGC stimulation totally reverses hypoxia-induced pulmonary vasoconstriction alone and combined with dual endothelin-receptor blockade in a porcine model.
    Lundgren J; Kylhammar D; Hedelin P; Rådegran G
    Acta Physiol (Oxf); 2012 Nov; 206(3):178-94. PubMed ID: 22682645
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Neurohormonal factors in heart failure. II].
    Cosín Aguilar J; Cruz Fernández JM; de Teresa Galván E; Ferreira Montero IJ; López-Sendón J; Soler Soler J; Tamargo Menéndez J
    Rev Esp Cardiol; 1996 May; 49(5):317-27. PubMed ID: 8744385
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Short-term endothelin receptor blockade with tezosentan has both immediate and long-term beneficial effects in rats with myocardial infarction.
    Clozel M; Qiu C; Qiu CS; Hess P; Clozel JP
    J Am Coll Cardiol; 2002 Jan; 39(1):142-7. PubMed ID: 11755300
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.